Cargando…

Does neoadjuvant chemoradiotherapy increase the effect of lateral lymph node dissection on urogenital function?

BACKGROUND: It is unclear whether neoadjuvant chemoradiotherapy (nCRT) has a deleterious influence on urogenital function in rectal cancer patients who undergone lateral lymph node dissection (LLND). The purpose of this study was to determine the incidence of urogenital dysfunction following total m...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yujuan, Zhou, Sicheng, Pei, Wei, Chen, Jinghua, Liang, Jianwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091023/
https://www.ncbi.nlm.nih.gov/pubmed/35571646
http://dx.doi.org/10.21037/tcr-22-87
_version_ 1784704843321966592
author Jiang, Yujuan
Zhou, Sicheng
Pei, Wei
Chen, Jinghua
Liang, Jianwei
author_facet Jiang, Yujuan
Zhou, Sicheng
Pei, Wei
Chen, Jinghua
Liang, Jianwei
author_sort Jiang, Yujuan
collection PubMed
description BACKGROUND: It is unclear whether neoadjuvant chemoradiotherapy (nCRT) has a deleterious influence on urogenital function in rectal cancer patients who undergone lateral lymph node dissection (LLND). The purpose of this study was to determine the incidence of urogenital dysfunction following total mesorectal excision (TME) + LLND with or without nCRT for mid-low rectal cancer, as well as to investigate the factors that predict urogenital dysfunction. METHODS: From January 2015 to December 2020, a total of 106 consecutive patients who underwent TME + LLND surgery for mid-low rectal cancer were reviewed. Patients were divided into two groups based on whether they had undergone nCRT (n=51) or not (n=55). RESULTS: Overall, 106 patients responded to the questionnaires. nCRT was not associated with urinary dysfunction [International Prostatic Symptom Score (IPSS): 9.86 vs. 9.43, P=0.778; postoperative urinary dysfunction: 51.0% vs. 34.5%, P=0.087] or male sexual dysfunction [International Index Erectile Function (IIEF) score: 18.45 vs. 18.42, P=0.980; postoperative sexual dysfunction: 61.3% vs. 54.8%, P=0.607]. According to the univariable analyses, tumour distance from the anal verge ≤4 cm (P=0.029) and type of operation (P=0.020) were associated with an increased risk of urinary dysfunction; patients’ age (P=0.026) and type of LLND (P=0.044) were candidate risk factors for male sexual dysfunction. However, multivariable analyses showed that tumour distance from the anal verge was independently associated with urinary dysfunction (OR =2.505; 95% CI: 1.080–5.813; P=0.032); patients’ age was an independent risk factor for male sexual dysfunction (OR =3.654; 95% CI: 1.028–12.982; P=0.045). CONCLUSIONS: In rectal cancer patients who had LLND, nCRT showed no significant additive effect on genitourinary function as compared to individuals who had TME + LLND alone. Urinary dysfunction was linked to the distance between the tumor and the anal margin, while age was an independent predictor of sexual dysfunction.
format Online
Article
Text
id pubmed-9091023
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-90910232022-05-12 Does neoadjuvant chemoradiotherapy increase the effect of lateral lymph node dissection on urogenital function? Jiang, Yujuan Zhou, Sicheng Pei, Wei Chen, Jinghua Liang, Jianwei Transl Cancer Res Original Article BACKGROUND: It is unclear whether neoadjuvant chemoradiotherapy (nCRT) has a deleterious influence on urogenital function in rectal cancer patients who undergone lateral lymph node dissection (LLND). The purpose of this study was to determine the incidence of urogenital dysfunction following total mesorectal excision (TME) + LLND with or without nCRT for mid-low rectal cancer, as well as to investigate the factors that predict urogenital dysfunction. METHODS: From January 2015 to December 2020, a total of 106 consecutive patients who underwent TME + LLND surgery for mid-low rectal cancer were reviewed. Patients were divided into two groups based on whether they had undergone nCRT (n=51) or not (n=55). RESULTS: Overall, 106 patients responded to the questionnaires. nCRT was not associated with urinary dysfunction [International Prostatic Symptom Score (IPSS): 9.86 vs. 9.43, P=0.778; postoperative urinary dysfunction: 51.0% vs. 34.5%, P=0.087] or male sexual dysfunction [International Index Erectile Function (IIEF) score: 18.45 vs. 18.42, P=0.980; postoperative sexual dysfunction: 61.3% vs. 54.8%, P=0.607]. According to the univariable analyses, tumour distance from the anal verge ≤4 cm (P=0.029) and type of operation (P=0.020) were associated with an increased risk of urinary dysfunction; patients’ age (P=0.026) and type of LLND (P=0.044) were candidate risk factors for male sexual dysfunction. However, multivariable analyses showed that tumour distance from the anal verge was independently associated with urinary dysfunction (OR =2.505; 95% CI: 1.080–5.813; P=0.032); patients’ age was an independent risk factor for male sexual dysfunction (OR =3.654; 95% CI: 1.028–12.982; P=0.045). CONCLUSIONS: In rectal cancer patients who had LLND, nCRT showed no significant additive effect on genitourinary function as compared to individuals who had TME + LLND alone. Urinary dysfunction was linked to the distance between the tumor and the anal margin, while age was an independent predictor of sexual dysfunction. AME Publishing Company 2022-04 /pmc/articles/PMC9091023/ /pubmed/35571646 http://dx.doi.org/10.21037/tcr-22-87 Text en 2022 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Original Article
Jiang, Yujuan
Zhou, Sicheng
Pei, Wei
Chen, Jinghua
Liang, Jianwei
Does neoadjuvant chemoradiotherapy increase the effect of lateral lymph node dissection on urogenital function?
title Does neoadjuvant chemoradiotherapy increase the effect of lateral lymph node dissection on urogenital function?
title_full Does neoadjuvant chemoradiotherapy increase the effect of lateral lymph node dissection on urogenital function?
title_fullStr Does neoadjuvant chemoradiotherapy increase the effect of lateral lymph node dissection on urogenital function?
title_full_unstemmed Does neoadjuvant chemoradiotherapy increase the effect of lateral lymph node dissection on urogenital function?
title_short Does neoadjuvant chemoradiotherapy increase the effect of lateral lymph node dissection on urogenital function?
title_sort does neoadjuvant chemoradiotherapy increase the effect of lateral lymph node dissection on urogenital function?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091023/
https://www.ncbi.nlm.nih.gov/pubmed/35571646
http://dx.doi.org/10.21037/tcr-22-87
work_keys_str_mv AT jiangyujuan doesneoadjuvantchemoradiotherapyincreasetheeffectoflaterallymphnodedissectiononurogenitalfunction
AT zhousicheng doesneoadjuvantchemoradiotherapyincreasetheeffectoflaterallymphnodedissectiononurogenitalfunction
AT peiwei doesneoadjuvantchemoradiotherapyincreasetheeffectoflaterallymphnodedissectiononurogenitalfunction
AT chenjinghua doesneoadjuvantchemoradiotherapyincreasetheeffectoflaterallymphnodedissectiononurogenitalfunction
AT liangjianwei doesneoadjuvantchemoradiotherapyincreasetheeffectoflaterallymphnodedissectiononurogenitalfunction